CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 100 enrolled
Drug / intervention
bimatoprost 0.01% +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02097719
NCT02097719Phase 4Completed
CompareCT.gov

Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Allergan·interventional·Posted Mar 27, 2014·Updated Jan 14, 2016

In Brief

A Phase 4 clinical trial evaluating bimatoprost 0.01%, travoprost 0.004%, and 2 other interventions for Glaucoma and Ocular Hypertension. Completed, enrolled 100 participants across 1 site.

Detailed Summary

This efficacy and safety study will evaluate LUMIGAN® .01 (bimatoprost 0.01%) alone compared to TRAVATAN Z® (travoprost 0.004%) and TIMOLOL GFS, 0.5% (timolol 0.5% ophthalmic gel forming solution) in patients who require IOP lowering therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Ocular Hypertension
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 27, 2014
Enrollment StartMay 1, 2014
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 12.3 years ago

Interventions

bimatoprost 0.01%drug

Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.

travoprost 0.004%drug

Travoprost 0.004% administered to both eyes once daily for 12 weeks.

timolol 0.5%drug

Timolol 0.5% administered to both eyes once daily for 12 weeks.

hypromellose 0.3%drug

Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.